Furthermore, comparison of GLI1 and SOX2 expression levels in 477 TCGA melanoma patients showed a co-expression of these two transcripts (p < 0.0001) (Fig. 1I) and a significant decrease in overall survival in cases with high expression of both SOX2 and GLI1 (p = 0.0213) (Fig. 1J). The gene discussed is SOX2; the disease is melanoma.